Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676935 · ClinicalTrials.gov registry record · Phase 2
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- Phase 2
- Development phase
- 349
- Enrollment target
NCT01676935 is a Phase 2 study that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 349 participants.
The verdict
NCT01676935, a Phase 2 study, was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 349 participants
- Enrollment target
Study Summary
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M10-985 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
Interventions
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676935
The ClinicalTrials.gov registry entry for NCT01676935 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-126 is the first listed.
NCT01676935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676935 about?
NCT01676935 is a clinical study titled "This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease". This is a long term extension study to evaluate safety and tolerability of subjects who complete study M10-985 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT01676935?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2012-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01676935?
The interventions under investigation include: ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01676935?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.